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Development of a therapeutic application of CASP3/caspase 3/CPP32, an executor of apoptosis, has been
challenging because regulation of its activation is complicated. This study aimed to inhibit cancer cell
growth and human immunodeficiency virus type 1 (HIV-1) propagation through a CASP3 mutant,
CASP3*, activable by HIV-1-encoded aspartate protease. Active CASP3* was delivered to leukemic cells
using a protein transduction vehicle, the lentivirus-like nanoparticle (LENA), which should contain
thousands of CASP3*-Gag protein molecules and release the activated CASP3* into the target cell
cytoplasm. CASP3*-LENA induced apoptosis in various types of leukemic cells. In addition to being
effectiveagainstleukemiccells,constitutiveexpressionofCASP3*restrictedHIV-1propagationinSUP-T1
cells. The attenuation of HIV-1 replication in SUP-T1/CASP3* cells was attributed to the elimination of
HIV-1-infected cells by apoptosis. These data suggest that CASP3* has therapeutic potential against both
lymphoid malignancies and HIV-1 infection.
C
ASP3 is expressed as an inactive pro-enzyme that is activated upon exposure to apoptosis-inducing
stimuli
1,2.Pro-CASP3undergoesproteolyticprocessingbyCASP8,9and10thatyieldsthreepolypeptides:
the pro domain, p17 and p12. The p17 and p12 form a heterodimer that executes the protease activity.
CASP3 activates itself as well as CASP6, 7 and 9 by proteolytic cleavage and amplification of the signal for the
executionofapoptosis.ThetherapeuticapplicationofCASP3islimitedbecauseofthiscomplexregulation
3–5.We
overcome this problem by genetic engineering the CASP3.
Here, a mutant of CASP3 designed to be activated specifically by the aspartate protease of human immunodefi-
ciency virus type 1 (HIV-1), but not by other CASPs, was produced (CASP3*) and a proof-of-concept study was
conducted to demonstrate the therapeutic potential of CASP3* against lymphoid malignancies and HIV-1 infection.
To achieve leukemic cell killing by CASP3*, a lentivirus-like nanoparticle (LENA) system was utilized
6. The
LENA system is a simple, efficient and reproducible method that we have developed to transduce proteins into
mammaliancells
6.TheLENAisdifferentfromlentiviralvectorinthattheformersystemdeliversproteinsthatare
encapsidatedintothenanoparticlesbutnotgenesasdoesthelatter.Proteintransductiondoesnotrequiredenovo
transcription and translation, and the transferred protein functions immediately after the transduction. Also,
LENAisbiologicallysafesinceLENAisnotan‘‘infectious’’agent.Approximately5,000CASP3*-Gagproteinsare
packaged, processed and activated by HIV-1 protease in the particle of LENA. CASP3*-LENA, facilitated by
vesicular stomatitis virus G protein (VSV-G), binds to cells and enters them via endocytosis. Membrane fusion
between the cell and LENA takes place at the endosome in a VSV-G-dependent manner. The LENA content is
thenreleasedintothecellcytoplasm.WeexpectedaninitiationofapoptosisinCASP3*-LENA-exposedleukemic
cells immediately after membrane fusion.
In the HIV/AIDS field, clinical trials have proved that gene therapy approaches are indeed effective against
HIV-1 infection
7,8.However,the emergenceof treatment-resistant viruses isproblematic, sinceHIV-1isahighly
mutagenic virus. Also, the ‘‘off-target’’ effect of therapeutic molecules is a serious concern. Thus, developing a
highly specific therapeutic gene against HIV-1 provides another option for treatment of HIV-1-infected indivi-
duals in a molecular therapy approach.
In this study, the genetically-engineered CASP3 activated specifically by HIV-1 protease was shown to have
therapeutic potential against both lymphoid malignancies and HIV-1 infection.
Results
CASP3* has proteolytic cleavage sites for HIV-1 protease adopted from the matrix (MA or p17
MA)-capsid (CA
or p24
CA) junction of HIV-1 Pr55
Gag (Gag, Fig. 1a). The myristoylation signal of Lyn was attached at the
amino-terminus and serves as a membrane-targeting signal. The pro domain of CASP3 was dispensable for
enzymeactivityandwasremovedfromthisconstruct.Then,theCASP3*wasappliedtotheLENAsystemforthe
leukemic cell killing experiment (Fig. 1b). The CASP3*-Gag and its proteolytic products were detected in the
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SCIENTIFIC REPORTS | 2 : 359 | DOI: 10.1038/srep00359 1Figure 1 | Construction, production and characterization of CASP3*-LENA. (a) Genetic structure of CASP3 and the genetic modification to produce
HIV-1 protease-activable CASP3*. The cellular (gray triangle, digesting D28-S29 and D175-S176 junctions) and HIV-1 (black triangle) protease
proteolytic sites are indicated. The CASP3 D28 was replaced with amino acids 127–136 (VSQNYPIVQ) from HIV-1 Gag (according to the HXB2
coordinate). The amino acids 129–134 (QNYPIV) from HIV-1 Gag according to the HXB2 coordinate was inserted after CASP3 D175. HIV-1 protease
targets the YP junction. The enzyme is active when the p17 and p12 subunits are dimerized. (b) Production of CASP3*-LENA and its mechanism of
action. The CASP3* was placed at the 5’ end of wild type (WT) gag-pol to yield CASP3*-gag-pol. The proteolytic cleavage sites within Gag for HIV-1
protease and the proteolytic products are indicated MA, matrix; CA, capsid; and NC, nucleocapsid. The CASP3*-gag-pol and VSV-G expression vectors
wereco-transfectedinto293Tcells.Then,theVSV-G-encapsidatedLENAcontainingactivatedCASP3*proteinwasproducedintheculturesupernatant.
CASP3*-LENA enters cells via an endocytotic route, with the content released from endosomes at the site of membrane fusion. The action points of
BafilomycinA1(BAF)andtheCASP3inhibitorZ-DEVD-FMKareindicated.(c)ExpressionofCASP3*-gag-polandCASP3*-LENAproduction.Thecell
lysates (Cell) and culture supernatants (Sup) of 293T cells transfected with either wild type (WT) or CASP3*-gag-pol (CASP3*) expression vector were
analyzed by Western Blot. The corresponding protein for each band is indicated. (d) Immunofluorescence assay showing the distribution of WT Gag or
CASP3*-Gag (CASP3*) in293T cells transfected witheither WTor CASP3*-gag-pol (CASP3*) expression vector. Red and bluerepresent the anti-p24
CA
monoclonalantibody-stainedsignalandtheHoechst33258-stainednucleus,respectively.Magnification, x630;scalebar,10 mm.(e)DetectionofCASP3
enzyme activity in purified CASP3*-LENA. CASP3*-LENA was produced either in the presence or absence of nelfinavir (NFV) and collected by
ultracentrifugationovera20%sucroselayer.DMSOwasusedasacontrol.TheamountofCASP3*-LENAandthecleavagepatternofGagwereexamined
by Western blot (left). CASP3 enzyme activity was detected in the CASP3*-LENA lysate (right).
www.nature.com/scientificreports
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analysis (Fig. 1c, Cell) in a pattern similar to that of wild-type Gag-
pol (WT, Fig. 1c). However the processing efficiency of Gag was
slightly attenuated in the CASP3* construct compared with WT,
as highlighted by the smaller amount of p24
CA relative to its pre-
cursor.Intheculturesupernatantoftransfected293Tcells,CASP3*-
LENA was detected by Western blot analysis (Fig. 1c, Sup). The
presence of CASP* was verified by Western blot analysis using
anti-CASP3 antibody that specifically recognizes the p17 subunit
of CASP3 (Fig. 1c, Sup). In 293T cells transiently transfected with
the WT expression plasmid, Gag was evenly distributed in the cell
cytoplasmasvisualizedbyanimmunofluorescenceassay(Fig.1d).In
contrast, CASP3*-Gag was distributed mainly in the cytoplasm and,
toalesserextent,inthenucleus,formingnumerousfineaggregations
(Fig. 1d). Also, some CASP3*-Gag signal was detected at the cell
periphery (Fig. 1d). Despite these differences, LENA production by
CASP3*-Gag-pol was as efficient as that by WT; the signal ratio of
CASP3*-Gag and its proteolytic products in the virus-like particle
(VLP) fraction relative to the cell lysate were comparable to that of
the WT (Fig.1c).
To verify the enzyme activity of CASP3* in LENA, the proteolytic
activity of CASP3* was measured using a caspase 3/7-specific sub-
strate, DEVD-aminoluciferin, that luminesces upon cleavage.
Significant enzymatic activity was detected in the purified
CASP3*-LENA (Fig. 1e). Importantly, this signal was substantially
reduced when proteolytic cleavage of CASP3*-Gag was attenuated
throughthepreparationofCASP3*-LENAinthepresenceof0.5 mM
HIV-1 protease inhibitor nelfinavir (NFV; Fig. 1e). These data sug-
gest that active CASP3* is enveloped in the LENA and that the
activation of CASP3* is dependent on HIV-1 protease.
HIV-1 protease is fully activated after viral budding. Thus, the
majorityofCASP3*shouldbeactivatedoutsidecells.Thisminimizes
damage to LENA-producing cells by CASP3*. However, LENA-
producing 293T cells were damaged upon Gag-pol expression pre-
sumably due to the cytotoxicity of the small amount of HIV-1
protease activated in the cell cytoplasm upon overexpression of the
protein. Cell viability and LENA production improved when the
LENA-producing cells were treated with a low dose of HIV-1 prote-
ase inhibitor. Preparation of LENA in the presence of 0.2 mM saqui-
navir (SQV) increased the LENA yield by approximately 4-fold
(Fig.2a).Undertheseconditions,HIV-1proteaseinLENAremained
active as evidenced by the production of cleavage intermediates of
CASP3*-Gag (Fig. 2a). The activation of CASP3* was not blocked
under these conditions because a cleavage intermediate, MA-CA,
predicatedtherelease of CASP3*fromthe precursor(Fig.2a,arrow-
head), and the biological activity of CASP3*-LENA was detected as
described below. Similar data were obtained using the low dose of
NFV.
For leukemic cell killing by CASP3*-LENA, an acute T cell lym-
phoblastic leukemia (ALL) cell line, MOLT-4, was chosen. MOLT-4
cell viability was significantly attenuated when cells were exposed to
CASP3*-LENA, whereas no cell killing was observed in WT-LENA
or non-enveloped CASP3*-LENA at 1d post-LENA exposure
(Fig. 2b and 2c). A cellmetabolism-basedcell viability assay revealed
that 93.3% of cell viability was lost in CASP3*-LENA-exposed
MOLT-4 cells at 1d post-LENA exposure (Fig. 2b). This cell killing
was more efficient when cells were treated with CASP3*-LENA pre-
pared in the presence of 0.2 mM SQV bearing a higher LENA titer
(99.2%, Fig. 2b). The MOLT-4 cells exposed to CASP3*-LENA con-
tained fragmented nuclei with condensed chromatin, characteristic
of cells undergoing apoptosis (Fig. 2d). Such nuclear morphology
was not found in MOLT-4 cells exposed to WT-LENA or non-
enveloped CASP3*-LENA. Induction of apoptotic cell death was
detected at 6 h post-LENA exposure by Annexin V staining
(Fig. 2e). The VSV-G functional inhibitor Bafilomycin A1, which
prevents the endosome acidification required for the activation of
VSV-G, rescued the cells from apoptotic cell death at 12.5 ng ml
21
(Fig. 2c-f). A cell-permeable CASP3 inhibitor, Z-DEVD-FMK, also
protected cells from CASP3*-LENA-induced apoptosis at 0.5 mM
(Fig. 2c–g). These data suggest that the cell death induced by
CASP3*-LENAisdependentonVSV-Gfunctionandtheproteolytic
function of CASP3*. The death inducing titer of CASP3*-LENA for
MOLT-4 cell was 2.0 3 10
6 particles per milliliter, which was esti-
mated from the dose-dependent cell killing kinetics using serially
diluted CASP3*-LENA preparations (average of four independent
experiments).
InadditiontoMOLT-4cells,CASP3*-LENAinducedapoptosisin
twomoreleukemiccellmodels,SUP-T1cells,apleuraleffusionTcell
lymphoblastic lymphoma cell line, and the HTLV-1-transformed T
cell line M8166, a model for adult T cell leukemia (ATL, Fig. 2g).
Similar data were obtained in the human chronic myelogenous leu-
kemia (CML)-derived cell line K562 and the neuroblastoma cell line
NP-2 (data not shown). These data indicate that the cell killing
activity of CASP3*-LENA is not restricted to the leukemic cells. In
these experiments, WT-LENA and non-enveloped CASP3*-LENA
failed toinduce apoptosis. Thesedata demonstrate the attractiveness
of CASP3* protein transduction by LENA as a tool for molecular
cancer therapy. The cell killing activity of CASP3*-LENA was not
detected in primary blood mononuclear cells (data not shown). This
is presumably because the primary cells are inefficient to the LENA-
mediated protein delivery and/or to the CASP3-induced apoptosis,
orboth.ThissuggeststhattheCASP3*-LENAmayfavorcancercells
to induce apoptotic cell death.
CASP3*wasalsoappliedto limitHIV-1replication. Wehypothe-
sized that CASP3*-expressing T cells may be more susceptible to
apoptosis upon HIV-1 infection due to the expression of HIV-1
protease in infected cells. To this end, SUP-T1 cells were transduced
with CASP3* using a murine leukemia virus (MLV) vector, and two
independently isolated pairs of SUP-T1 cells were analyzed (Fig. 3a).
The rate of cell proliferation and the susceptibility to apoptosis
inducedbyaserimdepriviationinSUP-T1/CASP3*cellswereindis-
tinguishable from those in SUP-T1/Cont cells (data not shown).
Cells were exposed to a low- or high-dose HIV-1 preparation and
viral replication was monitored. In both isolates, HIV-1 propagation
in SUP-T1/CASP3* cells was attenuated regardless of the HIV-1
exposure dose (Fig. 3b). These data suggest that CASP3* can limit
the propagation of HIV-1 in tissue culture.
To determine the mechanism by which HIV-1 replication is
blocked, the viral entry phase and the production phase were inves-
tigated separately. If the virus-associated protease is responsible for
the activation of CASP3* at the viral entry phase, infection with the
HIV-1-based lentiviral vectorshouldalsokillSUP-T1/CASP3*cells.
Thus, the establishment efficiency of lentiviral vector infection in
SUP-T1/CASP3* cells should be lower than that in control cells.
To test this, SUP-T1/CASP3* cells were infected with a lentiviral
vector expressing luciferase upon establishment of infection. The
luciferase activity in SUP-T1/CASP3* cells at 4 d post-infection
was lower than in the control cells (Fig. 3c). On the other hand,
the levels of MLV-transduced luciferase activity in SUP-T1/
CASP3* cells were similar to those in the control cells (Fig. 3c).
Note that CASP3* was not activated by MLV since the substrate
preference of MLV protease is distinct from that of HIV-1 protease.
Thesedatasuggestthatvirus-associatedHIV-1proteaseiscapableof
activating CASP3* to induce apoptosis in SUP-T1/CASP3* cells.
Luciferase activity was still detected in the lentiviral vector-infected
SUP-T1/CASP3* cells (Fig. 3c), implying that some cells might have
lostthehigh-levelexpressionofCASP3*orasinglevirion-associated
protease might not be able to initiate CASP3* activation at levels
sufficient to kill all of the infected cells. Next, the induction of apop-
tosis by the virion-associated viral protease was examined directly.
SUP-T1/CASP3* cells were exposed to HIV-1 and the cells were
probed with Annexin V. At 6 h post-infection, 2.7% of SUP-T1/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 359 | DOI: 10.1038/srep00359 3Figure 2 | Induction of apoptosis in leukemic cells by CASP3*-LENA. (a) Enhancement of WT- and CASP3*-LENA production by a low dose of
saquinavir (SQV, 0.2 mM). DMSO was used as a solvent control. The arrowhead indicates a signal representing the MA-CA, indicating the release of
CASP3* from CASP3*-Gag. (b) Quantitative analysis ofMOLT-4 cell viability after LENA exposure. Cell viability wasscored by colorimetric assay at 1d
post-LENA exposure comparing WT-LENA encapsidated with VSV-G (WT/VSV-G), non-enveloped CASP3*-LENA (ENV(-)), and CASP3*-LENA
encapsidatedwithVSV-G.TheaverageandstandarddeviationfromtriplicatedwellsusingLENAproducedinthepresenceorabsenceofSQVareshown
(SQVandDMSO, respectively).(c)Light microscopic observation ofMOLT-4cells treatedwithLENAproduced inthe presence oflow-dose SQV.Cells
wereimagedat1dpost-LENAexposure.CellsweretreatedwitheitherBafilomycinA1(BAF)ortheCASP3inhibitorZ-DEVD-FMK.DMSOwasusedas
a solvent control. Bar, 50 mm; magnification x100. (d) Nuclear morphology of MOLT-4 cells treated with LENA produced in the presence of low-dose
SQV. Cells were imaged at 1 d post-LENA exposure after staining with Hoechst dye. Cells were treated with either BAF or Z-DEVD-FMK. DMSO was
used as a solvent control. Bar, 10 mm; magnification x630. (e) Flow cytometric detection of apoptotic MOLT-4 cells. Cells were stained with Annexin V
Alexa Fluor 488 at 6 h post-exposure to LENA produced in the presence of low dose nelfinavir (NFV, 0.2 mM). The live cell fraction was gated to analyze
theearlyphaseofapoptoticcelldeath.CellsweretreatedwitheitherBAForZ-DEVD-FMK.DMSOwasusedasasolventcontrol.RLU,relativelightunits.
(f)QuantitativeanalysisofMOLT-4cellviabilityafterexposuretoLENAproducedinthepresenceoflow-doseNFV(0.2 mM).Cellviabilitywasscoredat
1d post-LENA exposure. Cells were treated with either BAF or Z-DEVD-FMK. DMSO was used as a solvent control. (g) Quantitative analysis of M8166
and SUP-T1 cell viabilities as perfomed on MOLT-4 cells.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 359 | DOI: 10.1038/srep00359 4Figure 3 | Inhibition of HIV-1 propagation by CASP3*. (a) Schematic representation of the experimental approach. SUP-T1 cells were infected with
MLVcarryingtheCASP3*toproducecellsconstitutivelyexpressingCASP3*.ThesecellswereinfectedwithHIV-1,andthereplicationefficiencyofHIV-
1wasmeasuredusingviralp24
CAantigeninthecellculturemedium.(b)InhibitionofHIV-1NL4-3replicationinSUP-T1/CASP3*cells.Cellswereexposed
to high- or low-dose viral preparation yielding 25 ng or 1.3 ng of p24
CA per 1 3 10
5 cells, respectively. The viral p24
CA concentration in the culture
supernatantwasmeasuredat6–9dpost-viralinfection.ResultsshownwereobtainedfromtwoindependentisolatesofSUP-T1/CASP3*andcontrolcells.
(c) Analysis of SUP-T1/CASP3* cell fate after HIV-1 entry. Luciferase activity of cells infected with either an HIV-1-based lentiviral vector or an MLV
vectorwasmeasuredat4 dpost-infection. RLU,relativelightunits.(d)Flowcytometric detectionofapoptotic SUP-T1/ContandSUP-T1/CASP3*cells
by HIV-1NL4-3 infection. The percentage of Annexin V Alexa Fluor 488 positive cells was measured at 6 h post-nelfinavir (NFV) exposure, post-HIV-1
infection, and post-HIV-1 infection in the presence of 2 mM NFV, and subtracted from the percentage of Annexin V positive cells in untreated controls.
Thelivecellfractionwasgatedaccordingtoscattertoanalyzetheearlyphaseofapoptoticcelldeath.Datafromtwoindependentexperimentsareshown.
For this experiment, cells from isolate #2 were used. (e) Analysis of SUP-T1/CASP3* cell fate upon HIV-1 production. The SUP-T1/CASP3* cells were
transduced with HIV-1 Gag-pol or Gag by either MLV vector (left panel) or transfection (right panel), and the expression of transduced proteins was
detected at 7 d post-gene transduction by Western blot. For the transfection experiment, cells were maintained in the presence of 0.5 mM NFV to detect
the effect of Pol on cell survical.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 359 | DOI: 10.1038/srep00359 5Cont cells underwent apoptosis, which was lowered by NFV
(Fig. 3d), suggesting that the HIV-1 infection induces apoptotic cell
death in a HIV-1 protease-dependent manner as previously
reported
9,10. By contrast, the apoptotic cells was detected more fre-
quently in SUP-T1/CASP3* cells than in SUP-T1/Cont cells (6.3%
and 5.0% in two independent experiments), which was drastically
decreased to 1.2% in the presence of NFV (Fig. 3d). These data
suggest that the CASP3* predispose cells to undergo apoptosis upon
HIV-1 infection, and the virus-associated protease is responsible for
the induction of apoptosis.
To examine the viral production phase, the HIV-1 gag-pol was
transducedintoSUP-T1/CASP3*cellsbyMLVvector,andthelevels
of Gag were evaluated. If HIV-1 protease activity in virus producing
cells is responsible for the activation of CASP3*, then the expression
of Gag-pol, not Gag, should confer the cell growth disadvantage,
resulting in reduced levels of Gag in these cells. Transfected SUP-
T1/CASP3*cellsweresubjectedtoWesternBlotanalysisat7dpost-
infection. The levels of Gag and its proteolytic products in SUP-T1/
CASP3* cells were indistinguishable from those of the control cells
(Fig. 3e). Similar results were obtained when SUP-T1/CASP3* cells
were transfected with a plasmid expressing HIV-1 Gag-pol (Fig. 3e).
ThesedataindicatethattheattenuationofHIV-1replicationinSUP-
T1/CASP3* cells is due to the activation of CASP3* by virion-assoc-
iatedHIV-1proteaseattheviralentryphase,leadingtothedepletion
of virus-infected cells from the culture by apoptosis. In agreement
with this model, the inhibition of apoptosis by Z-DEVD-FMK
enhanced the efficiency of HIV-1 replication (data not shown).
Discussion
This study provides evidence that CASP3* has therapeutic potential
against cancer and HIV-1 infection, overcoming the potential dif-
ficulty of CASP3 for the application to human gene therapy
3,4,11. The
cancer therapy by CASP3*-LENA may be more applicable to solid
tumors due to the current technological limit in particle delivery.
However, to apply the CASP3*-LENA approach to the cancer ther-
apy, it is critical to improve the potency of CASP3*-LENA. This is
because the cell killing activities of CASP3*-LENA in some trans-
formed cells, including MT-4, a HTLV-1-transformed human T cell
line, were undetectable although the LENA-mediated protein deliv-
ery by LENA has been shown to be highly efficient in MT-4 cells
6.
MT-4 cells are highly resistant to apoptosis because they express
potent anti-apoptotic genes, such as HTLV-1 Tax
12–14. The Tax
induces expression of intracellular caspase inhibitor, cFLIP, which
inhibits the activation cycle of CASPs
15,16. Cancer cells often express
high levels of cellular inhibitor of apoptosis protein (CIAP), which
may lower the susceptibility of cells to apoptosis induced by CASP3.
We may be able to overcome this issue by generating a CASP3*
mutant that does not interact with CIAP. The potentiation of
CASP3*-LENA should also contribute to reduce the number of
injections necessary to achieve the therapeutic effect. Additionally,
for clinical applications, a regulatory system to control the cell trop-
ism of LENA needs to be developed.
For HIV-1 infection, CASP3* may be applicable to adoptive stem
cell therapy, alternatively termed intracellular vaccination. Stem cell
gene therapy has been shown to be effective in clinical trials against
HIV-1 infection, as has shRNA therapy targeting CCR5 mRNA
7.
Gene therapy using a zinc finger nuclease was found to be effective
againstHIV-1infectionaswell
8.Thesetherapeuticapproachestarget
nucleic acids, and off-target effects represent a serious concern.
CASP3* is designed to be activated specifically by HIV-1 protease;
thus, it offers a basis for a novel therapeutic approach with few
"off-target" effects. CASP3* induces suicide in HIV-1-infected cells,
and does not yield latently-infected cells. The CASP3* approach
should be effective against drug-resistant HIV-1 strains since the
anti-viral mechanism of CASP3* is distinct from those of cur-
rently-available anti-retroviral drugs. Furthermore, a CASP3*-
resistant HIV-1 may not emerge easily. This is because mutations
in viral protease that do not affect Gag processing but also do not
activate CASP3* are unlikely to occur. Additionally, our strategy is
applicable to other infectious diseases if the infectious agents encode
proteases with unique substrate preferences. In summary, our work
provides aplatform forthe development of aCASP3*-based therapy
against cancer and HIV-1 infection.
Methods
Plasmids. CASP3 was amplified from MT-4 total RNA using a two-step PCR
protocol. For the first reaction, two RT-PCR reactions were performed using the
followingprimersets:fwd#15’-accggtcAGCCAGAACTACcccatcgtgcagTCTgg
aatatccctggacaac-3’andrev#15’-CTcacgatgggGTAGTTCTGgtctgtctcaatgcca
cag tc-3’; and fwd #2 5’-acC AGA ACT ACc cca tcg tgA GTG GTG TTG ATG ATG
ACA TGG-3’ and rev #2 5’-CAA TTG GTG ATA AAA ATA GAG TTC TTT TG-3’.
The second PCR reaction was performed using fwd #1 and rev #2 primers targeting
the products obtained in the first RT-PCR reactions. The AgeI-MfeI fragment of the
PCR product was cloned into AgeI-EcoRI sites of plynMyGFP-gag-pol
6, generating
pCASP3*-gag-pol. The retroviral expression vector pQcCASP3* was constructed by
amplifying CASP3* by PCR as detailed above using 5’-acc ggt gcc acc ATG ggc TCT
gga ata tcc ctg gac aac-3’ and 5’-CAA TTG TTA GTG ATA AAA ATA GAG TTC
TTT TG-3’, and cloned into AgeI-EcoRI sites of pQcXIP (Clontech, Palo Alto, CA).
The pCMMP Gagf vector was constructed by cloning a XhoI-BamHI fragment from
pGag-GFP
17 into the corresponding restriction sites of pCMMP KRAB
18.T h e
pCMMP HIV-1 gag-pol IRES GFP was constructed by three step cloning. First, the
AgeI-BamHI KRAB gene fragment from pCMMP KRAB was cloned into the
corresponding restriction sites of pCMMP LacZ IRES GFP
9, generating pCMMP
KRAB IRES GFP. The AgeI-EcoRI BlaM gene fragment amplified from pUC19 by
PCR
6 was cloned into the AgeI-MfeI sites of pCMMP KRAB IRES GFP, generating
pCMMP BlaM IRES GFP. The EcoRI-XhoI HIV-1 gag-pol gene fragment from pgag-
pol
18 was cloned into the corresponding restriction sites of pCMMP BlaM IRES GFP,
generatingpCMMPHIV-1gag-polIRESGFP.TheHIV-1proviralDNApNL4-3was
obtained from the NIH AIDS Research and Reference Program. The HIV-1 Gag
expression vector pHIV-1 Gagf was produced by cloning an AgeI-BamHI fragment
from pHIV-1 Gagf-GFP
17 into the corresponding sites of pEGFP-C2 (Clontech).
Cells, viability assay, and transfection. Cells were maintained in RPMI 1640
medium (Sigma, St. Louis, MA) supplemented with 10% fetal bovine serum (Japan
Bioserum, Tokyo), 100 U ml
21 penicillin, and 100 mgm l
21 streptomycin
(Invitrogen),at37uCinahumidified5%CO2atmosphere.Cellsweretransfectedwith
Lipofectamine 2000 according to the manufacturer’s protocol (Invitrogen).
Bafilomycin A1 was used at a concentration of 12.5 ng ml
21 (Sigma), and a CASP3
inhibitor, Z-DEVD-FMK, was used at a concentration of 0.5 mM (BioVision,
MountainView,CA).TheHIV-1proteaseinhibitorsnelfinavir(NFV)andsaquinavir
(SQV) wereobtained from the NIH AIDS Research and Reference ReagentProgram.
To produce VSV-G-pseudotyped LENA, 200 ng pVSV-G (Clontech) and 2 mg
pCASP3*-gag-pol or pgag-pol
18 were transfected into 293T cells. Non-enveloped
LENA was produced using pcDNA3 (Invitrogen) in place of pVSV-G. The LENA
preparation was passed through nitrocellulose filters (0.45 mm). Cell viability was
scoredbytheCellTiter96AqueousOneSolutionCellProliferationAssay(Promega).
For the transfection of plasmids into SUP-T1 cells, a DEAE-dextran protocol was
employed. Five million cells were resuspended in 250 ml of STBS (25 mM TrisCl, pH
7.4, 137 mM NaCl, 5 mM KCl, 0.6 mM Na2HPO4, 0.7 mM CaCl2, and 0.5 mM
MgCl2), including 10 mg of plasmid DNA. Cells were mixed with 250 mlo fS T B S
containing 1 mg ml
-1 of DEAE-dextran and incubated for 30 min at room
temperature (RT). The cells were then incubated with STBS containing 10% DMSO
for 2 min at RT and washed with 1 ml HBSS (Invitrogen).
Protein transduction. Protein transduction was performed as described previously
by incubating approximately 1 3 10
6 cells with 1 ml LENA-containing culture
medium at 37uC
3.
Immunological detection. The detection of viral gene products by Western blot
analysis was performed as described previously
19, except that the anti-p24
CA
monoclonal antibody clone 183-H12-5C and anti-CASP3 p17 subunit polyclonal
antibody (Cat. # AB3623, Millipore, Tokyo, Japan) were used. Immunofluorescent
analysis was performed as described previously using the same monoclonal
antibody
18. Signals were detected using an LAS-3000 mini Lumino-Image analyzer
operated by the LAS-300mini Image Reader software (ver.2.2, Fuji Film, Tokyo,
Japan). The brightness and contrast of the image were adjusted using Adobe
Photoshop (ver.7.0, Adobe, Tokyo, Japan).
Microscopy.Cells wereimaged byconfocalfluorescence microscopy (LSM510Meta,
CarlZeissMicroImagingInc.,Tokyo,Japan).Fortheimagingofnuclei,multiplefocal
planes were projected to generate a single image.
Virus production and infection. The HIV-1, lentiviral and MLV vectors used have
been described previously
9. The pQcXIP was used as a control for pQcCASP3*.
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was purchased from Promega (Caspase-Glo 3/7 Assay System, Promega, Madison,
WI). Luciferase activity was measured using the Steady-Glo Luciferase Assay system
(Promega). Luminescence was detected using a Veritas
TM Microplate Luminometer
(Promega).
AnnexinVapoptosisassay.CellswereanalyzedbyflowcytometryusingtheVybrant
Apoptosis Assay kit (Invitrogen).
Enzyme-Linked Immunosorbent Assay (ELISA). A p24 ELISA was conducted
according to the manufacturer’s protocol (Zeptometrics, Buffalo, NY). To measure
cellularp24,transfected293Tcells werewashedoncewithPBS, lysedin500 mlbuffer
A (described above) for 30 min, and then subjected to the ELISA.
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